European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-27

METABOLIC BASIS OF NEURODEGENERATIVE DISEASE

Cel

Alzheimer disease (AD) is the most common form of age-related dementia affecting millions of patients worldwide. Disturbingly, disorders of lipid and glucose metabolism emerge as major risk factors for onset and progression of neurodegeneration in the human population. Thus, an increasing life expectance combined with an observable rise in metabolic disturbances is expected to turn AD into one of the most serious health problems for future generations. Still, the molecular mechanisms whereby dysregulation of glucose and lipid homeostasis elicits noxious insults to the brain remain poorly understood. We characterized a novel class of intracellular sorting receptors, termed VPS10P domain receptors with dual roles in regulation of neuronal viability and function, but also in modulation of glucose and lipid homeostasis. Our proposal aims at elucidating an important yet poorly understood link between metabolism and neurodegeneration that converges on these receptors. Our approach is unique and novel in several ways. Thematically, our studies focus on a novel class of receptors previously not considered. Based on the receptors’ ability to act as sorting proteins, we propose faulty protein trafficking as a major unifying concept underlying neurodegenerative and metabolic disorders. Conceptually, our approach relies on the interdisciplinary effort of neuroscientists and metabolism researchers working jointly on pathophysiological pathways converging on these receptors. Through this effort, we are confident to gain important insights into the crosstalk between brain and peripheral tissues, and to elucidate pathways common to metabolic disturbances and dementia, two prevailing degenerative disorders inflicting our societies.

Zaproszenie do składania wniosków

ERC-2013-ADG
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

ERC-AG - ERC Advanced Grant

Instytucja przyjmująca

MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Wkład UE
€ 2 415 229,00
Adres
ROBERT ROSSLE STRASSE 10
13125 Berlin
Niemcy

Zobacz na mapie

Region
Berlin Berlin Berlin
Rodzaj działalności
Research Organisations
Kierownik naukowy
Thomas Franz Erich Willnow (Prof.)
Kontakt administracyjny
Ioannis Legouras (Dr.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)